Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: Design, synthesis, and biological activity evaluation

Journal of Medicinal Chemistry

Volumn 48, Issue 20, 2005, Pages 6379-6385

  Cepa, Margarida M D S ^a,b   Tavares Da Silva, Elisiário J ^c   Correia Da Silva, Georgina ^a,b   Roleira, Fernanda M F ^c   Teixeira, Natércia A A ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA,4ALPHA EPOXY 5ALPHA ANDROSTAN 17 ONE; 5ALPHA ANDROST 3 EN 17 ONE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; STEROID; TESTOLACTONE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANDROSTANES; ANDROSTENEDIONE; AROMATASE INHIBITORS; CYCLOPENTANES; DRUG DESIGN; HUMANS; LACTONES; MICROSOMES; PLACENTA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 26444502089     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050129p     Document Type: Article

References (28)

1. Miller, W. R. Biological Rational for Endocrine Therapy in Breast Cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2004, 18, 1-32.
2. Henderson B. E.; Ross R. K.; Pike M. C.; Casagrande, J. T. Endogenous Hormones as a Major Factor in Human Cancer. Cancer Res. 1982, 42, 3232-3239.
3. Sedlacck, S. M.; Horwitz, K. B. The Role of Progestins and Progesterone Receptors in the Treatment of Breast Cancer. Steroids 1984, 44, 467-484.
4. McGuire, W. R. An Update on Estrogen and Progesterone Receptors in Prognosis for Primary and Advanced Breast Cancer. In Hormones and Cancer; Iacobelli, S., King R. J. B., Linder H. R., et al., Eds.; Raven Press: New York, 1980; Vol. 14, pp 337-344.
5. Hemsell, D. L.; Grodin, J.; Breuner, P. F. Plasma Precursors of Estrogen. II. Correlation of the Extent of Conversion of Plasma Androstenedione to Estrone with Age. J. Clin. Endocrinol. Metab. 1974, 38, 476-479.
6. Ackerman, G. E.; Smith M. E.; Mendelson, C. R.; MacDonald, P. C.; Simpson, E. R. Aromatization of Androstenedione by Human Adipose Tissue Stromal Cells in Monolayer Culture. J. Clin. Endocrinol. Metab. 1981, 53, 412-417.
7. Miller, W. R.; Anderson, T. J.; Jack, W. J. L. Relationship Between Tumor Aromatase Activity, Tumor Characteristics and Response to Therapy. J. Steroid Biochem. Mol. Biol. 1990, 37, 537-548.
8. Njar, V. C. O.; Brodie, A. Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors. Drugs 1999, 58, 233-255.
9. Zumoff, B. Does Postmenopausal Estrogen Administration Increase the Risk of Breast Cancer? Contributions of Animal, Biochemical and Clinical Investigative Studies to a Resolution of the Controversy. Proc. Soc. Exp. Biol. Med. 1998, 217, 30-37.
10. Winer, E. P.; Hudis, C.; Burstein, H. J.; Chebowski, R. T.; Ingle, J. N.; Edge, S. B.; Mamounas, E. P.; Gralow, J.; Goldstein, L. J.; Pritchard, K. I.; Cobleigh, M. A.; Langer, A. S.; Perotti, J.; Powles, T. J.; Whelan, T. J.; Browman, G. P. Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002. J. Clin. Oncol. 2002, 20, 3317-3327.
11. Brodie, A. Aromatase Inhibitors and Hormone-Dependent Cancers. J. Steroid Biochem. Mol. Biol. 1990, 37, 327-333.
12. Bulun, S. E.; Zeitoun, K.; Takayama, K.; Noble, L.; Michael, D.; Simpson, E.; Johns, A.; Putman, M.; Sasano, H. Estrogen Production in Endometriosis and Use of Aromatase Inhibitors to Treat Endometriosis. Endocr. Relat. Cancer 1999, 6, 293-301.
13. Miller, W. R.; Jackson, J. The Therapeutical Potential of Aromatase Inhibitors. Expert. Opin. Investig. Drugs 2003, 12, 337-52.
14. Goss, P. E.; Coombes, R. L.; Powles, T. J. Treatment of Advanced Postmenopausal Breast Cancer with Aromatase Inhibitor, 4-hydroxyandrostenedione - Phase 2 Report. Cancer Res. 1986, 46, 4823-4826.
15. Numazawa, M.; Yamaguchi, S. Synthesis and Structure-Activity Relationships of 6-Phenylaliphatic-Substitued C19 Steroids Having a 1,4-diene, 4,6-diene or 1,4,6-triene Structure as Aromatase Inhibitors. Steroids 2001, 64, 187-196.
16. Numazawa, M.; Yamada, K.; Nitta, S.; Sasaki, C.; Kidokoro, K. Role of Hydrophilic Interaction in Binding of Hydroxylated 3-Deoxy C19 Steroids to the Active Site of Aromatase. J. Med. Chem. 2001, 44, 4277-4283 and references therein.
17. Numazawa, M.; Yoshimura, A.; Watari, Y.; Matsuzaki, H. Aromatase Inhibition by 4β,5β-Epoxides of 16α-Hydroxyandrostenedione and Its 19-Oxygenated Analogues, Potential Precursors of Estriol Production in the Feto-Placental Unit. Biol. Pharm. Bull. 2002, 25, 1566-1569.
18. Nagaoka, M.; Watari, Y.; Yajima, H.; Tsukioka, K.; Murai, Y.; Yamada, K.; Numazawa, M. Structure-Activity Relationships of 3-Deoxy Androgens as Aromatase Inhibitors. Synthesis and Biochemical Studies of 4-Substituted 4-Ene and 5-Ene Steroids. Steroids 2003, 68, 533-542.
19. Leclercq, G. Androgens and Other Androstane Derivatives: Aromatase Inhibitors; Lactones. In Antitumour Steroids: Blickenstaff, R. T., Ed.; Academic Press: New York, 1992; pp 65-122.
20. Tavares da Silva, E. J.; Roleira, F. M.; Sá e Melo, M. L.; Campos Neves, A. S.; Paixão, J. A.; Almeida, M. J.; Costa, M. M. R.; Andrade, L. C. R. X-ray and Deuterium Labeling Studies on the Abnormal Ring Cleavages of a 5β-Epoxide Precursor of Formestane. Steroids 2002, 67, 311-319.
21. Tavares da Silva, E. J.; Sá e Melo, M. L.; Campos Neves, A. S. Novel Approach to the Synthesis of the Aromatase Inhibtor 4-Hydroxyandrost-4- ene-3, 17-dione (4-OHA). J. Chem. Soc., Perkin Trans. 1 1996, 14, 1649-1650.
22. Tavares da Silva, E. J.; Sá e Melo, M. L.; Campos Neves, A. S.; Andrade, L. R. C.; Almeida, M. J. M.; Costa, M. M. R. Expedient Synthesis of Ring-D Lactones of Formestane and Related Androstanes as New Potential Aromatase Inhibitors. J. Chem. Soc., Perkin Trans. 1 1997, 23, 3487-3489.
23. Thompson E. A.; Siiteri P. K. Utilization of Oxygen and Reduced Nicotimamide Adenine Dinucleotide Phosphate by Human Placental Microsomes During Aromatization of Androstenedione. Biol. Chem. 1974, 249, 53-64.
24. Numazawa, M.; Mutsumi, A.; Tachibana, M.; Hoshi, K. Synthesis of Androst-5-en-7-ones and Androst-3,5-diene-7-ones and Their Related 7-Deoxy Analogues as Conformational and Catalytic Probes for the Active Site of Aromatase. J. Med. Chem. 1994, 37, 2198-2205.
25. Narashimamurthy, J.; Rao, A. R. R.; Sastry, G. N. Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment. Curr. Med. Chem.-Anti-Cancer Agents 2004, 4 (6), 523-534.
26. Yoshida N.; Osawa Y. Purification of Human Placental Aromatase Cytochrome P-450 with Monoclonal Antibody and Its Characterization. Biochemistry 1991, 30, 3003-3010.
27. Bradford, M. M. A Rapid and Sensitive Method for the Quantification of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal. Biochem. 1976, 72, 248-254.
28. Heidrich, D.; Steckelbroeck, S.; Klingmuller, D. Inhibition of Human Cytochrome P-450 Aromatase Activity by Butylins. Steroids 2001, 66, 763-769.